Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Swynghedauw B  
Cardiovascular Pharmacogenetics and Pharmacogenomics

Journal of Clinical and Basic Cardiology 2001; 4 (3): 205-210

PDF    Summary   

Keywords: GenetikKardiologiemedikamentenabbauende EnzymePharmakogenetikPharmakogenomikcardiologydrug-metabolising enzymesgeneticspharmacogeneticspharmacogenomics

The recent developments of genome-based technology provide to the pharmacologists and therapists new tools that allow genotypings focused on polymorphic drug-metabolizing enzymes, such as the cytochrome P450 enzyme, CYP family, or polymorphic drug targets proteins, such as lipoproteins or ion channels. Amongst the different allelic isoforms, there is evidence that several of these isoforms are functionally different and can metabolize drugs at different speeds or react to drug binding in a different way. In addition, drug metabolizing enzymes are frequently associated with a more general detoxification function, functionally different isoforms could then provide some interesting information concerning several toxic agents, which are cardiovascular risk factors such as tobacco or alcohol.
copyright © 2003–2018 Krause & Pachernegg GmbH | Sitemap | Impressum